Opinion|Videos|September 3, 2024
Luspatercept in Lower Risk MDS: Insights on the COMMANDS Trial
Medical experts offer insights on the COMMANDS trial findings.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Discuss the expanded indication of luspatercept in lower-risk myelodysplastic syndromes (based on the COMMANDS trial findings) and its implications for clinical practice.
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Multiagonists Outpace Older GLP-1 Drugs for Weight Loss
2
Physical Function Views Differ Between Older AML Patients, Clinicians
3
Evolocumab Cuts Death Risk for a First Heart Attack or Stroke
4
Better Cardiovascular Health Tied to Lower Overactive Bladder Risk
5